Status:
COMPLETED
Prognostic Value of SPECT-CT Quantitative Indices for the Response Assessment of Bone Metastatic Prostate Carcinoma
Lead Sponsor:
University Hospital, Brest
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
Prognostic interest of bone scintigraphy in bone metastatic prostate carcinoma (BMPC) has been shown. Recent technological advances allow to perform quantitative bone SPECT-CT in routine practice. The...
Detailed Description
Prostate adenocarcinoma is one of the most common cancer in men, and bone its most frequent distant metastasis location. 5-year survival has greatly increased these last two decades, with wide differe...
Eligibility Criteria
Inclusion
- Patients who underwent a bone SPECT-CT (Symbia INTEVO T6) between april 2014 and april 2017, with bone metastatic prostate cancer.
- No opposition of the patient to participate in the study.
Exclusion
- Opposition of the patient. Age\<18 y/o
Key Trial Info
Start Date :
January 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 30 2018
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT03382522
Start Date
January 1 2018
End Date
March 30 2018
Last Update
July 23 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHRU de Brest
Brest, France, 29609